JDD in the Media

Treatment of Plaque Psoriasis With an Excimer Laser Utilizing an Optimal Therapeutic UVB Dose Protocol

By April 13, 2020April 29th, 2020No Comments

Treatment of Plaque Psoriasis With an Excimer Laser Utilizing an Optimal Therapeutic UVB Dose Protocol

Psoriasis is a chronic, immune-mediated disease that mainly affects the skin and joints.

Treatment for psoriasis depends on the severity, along with many other factors, and limited psoriasis can often be treated with topical agents, while patients with moderate to severe disease may also need phototherapy by ultraviolet irradiation or systemic therapy.

During phototherapy treatments, therapeutic doses of ultraviolet light may be administered by broadband ultraviolet B (UVB) radiation (290-320 nm), narrowband UVB (311-313 nm), and PUVA – photochemotherapy with psoralen followed by ultraviolet A radiation (320-400 nm).6,7
A recent study published in the Journal of Drugs in Dermatology investigates the efficiency and efficacy of the Multi-Micro Dose® diagnostic tip accessory for STRATA’s proprietary XTRAC® 308nm excimer laser in treatment of plaque psoriasis:
[…] treatment with the excimer laser was well tolerated. Similar to previous reports,11,14-16 erythema was the most common adverse event. No erosions or hyperpigmentation were reported. Two patients experienced blistering after initiation of the actual treatment. Blistering is an expected side effect in phototherapy with the excimer laser, and is usually well tolerated by patients.14,17,18 Blistering might be related to the user’s techniques (overlapping of laser treatment fields), or it may occur if the plaque’s thickness varies.

The OTDTM protocol with the MMD tip allows adjusting the treatment dose with the excimer laser to specific plaques, resulting in more effective dosing levels and a lower frequency of treatment sessions.

Read More

You May Also Like

JDD in the News: Upadacitinib’s Potential Cardiovascular Effects 

| Acne, Derm Community, Featured Articles, JDD Highlights, JDD in the Media, The Latest | No Comments
Upadacitinib may provide additional health benefits, including reducing the risk of major adverse cardiovascular events (MACE) and venous thromboembolism (VTE). That’s according to a May Journal of Drugs in Dermatology…

Dermatology Roundup: Survey Shows Misconceptions About Sunscreen and Skin Aging

| JDD Highlights, JDD in the Media, The Latest | No Comments
By Allison Sit A new American Academy of Dermatology (AAD) survey shows American adults may not fully understand the benefits of sunscreen. The survey of 1,000 adults found nearly one…

What’s Old is New: The Translational Understanding of and Approaches to Dermatoporosis

| JDD Highlights, JDD Webinars, The Latest | No Comments
This webinar delves into the emerging field of dermatoporosis, a chronic skin fragility condition. Participants will explore the latest translational research that bridges basic science and clinical practice, enhancing our…

Leave a Reply